Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y. Umeda Y, et al. Among authors: kiniwa y. Eur J Cancer. 2021 Nov;157:361-372. doi: 10.1016/j.ejca.2021.08.034. Epub 2021 Sep 23. Eur J Cancer. 2021. PMID: 34563991
[Antibody therapies for melanoma].
Kiniwa Y, Okuyama R. Kiniwa Y, et al. Nihon Rinsho. 2012 Dec;70(12):2172-6. Nihon Rinsho. 2012. PMID: 23259392 Review. Japanese.
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y. Inoue H, et al. Among authors: kiniwa y. Oncoimmunology. 2016 Jun 30;5(9):e1204507. doi: 10.1080/2162402X.2016.1204507. eCollection 2016. Oncoimmunology. 2016. PMID: 27757299 Free PMC article.
Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T, Kiniwa Y, Sato R, Sano T, Nakamura K, Mikoshiba Y, Ohashi N, Sekijima Y, Okuyama R. Shirai T, et al. Among authors: kiniwa y. Eur J Cancer. 2019 Jan;106:193-195. doi: 10.1016/j.ejca.2018.10.025. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528803 No abstract available.
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, Isei T, Hayashi T, Shibayama Y, Yamazaki N. Nakamura Y, et al. Among authors: kiniwa y. Ann Oncol. 2020 Sep;31(9):1198-1206. doi: 10.1016/j.annonc.2020.05.031. Epub 2020 Jun 6. Ann Oncol. 2020. PMID: 32522691 Free article.
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y. Kawashima S, et al. Among authors: kiniwa y. J Immunother Cancer. 2021 Nov;9(11):e003134. doi: 10.1136/jitc-2021-003134. J Immunother Cancer. 2021. PMID: 34795004 Free PMC article.
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Nakamura Y, et al. Among authors: kiniwa y. ESMO Open. 2021 Dec;6(6):100325. doi: 10.1016/j.esmoop.2021.100325. Epub 2021 Nov 25. ESMO Open. 2021. PMID: 34839104 Free PMC article.
Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study.
Kato J, Namikawa K, Uehara J, Nomura M, Nakamura Y, Uhara H, Uchi H, Yoshikawa S, Kiniwa Y, Nakamura Y, Miyagawa T, Matsushita S, Takenouchi T, Hatta N, Ohno F, Maeda T, Fukushima S, Yamazaki N. Kato J, et al. Among authors: kiniwa y. Br J Dermatol. 2022 Oct;187(4):594-596. doi: 10.1111/bjd.21276. Epub 2022 Jun 7. Br J Dermatol. 2022. PMID: 35347707 No abstract available.
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).
Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, Uchi H, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, Yamazaki N. Kamimura A, et al. Among authors: kiniwa y. J Dermatol. 2022 Sep;49(9):837-844. doi: 10.1111/1346-8138.16422. Epub 2022 May 5. J Dermatol. 2022. PMID: 35510662
85 results